Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Bristol Myers Squibb Stock Rises
Bristol Myers Squibb Stock Rises After Schizophrenia Drug Gets FDA Approval
Key Takeaways Bristol Myers Squibb's drug to treat schizophrenia was approved for use by the Food and Drug Administration.The pharmaceutical firm called Cobenfy the first new treatment for the illness in decades.
Cobenfy Approval Brings 20% Upside To Bristol Myers Squibb Stock
This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic drugs.
Bristol-Myers Squibb: Unlocking Value With KarXT FDA Approval And Oncology Pipeline Progress
Bristol-Myers Squibb received FDA's approval for Cobenfy, which is poised to be a game changer in the treatment of Schizophrenia. See why BMY stock is a Buy.
Business Insider
15h
Bristol-Myers Squibb: Sell Rating Justified by Market Challenges and Drug Uptake Concerns
Terence Flynn, an analyst from Morgan Stanley, maintained the Sell rating on Bristol-Myers
Squibb
(BMY – Research Report). The associated price target remains the same with $37.00. Terence Flynn has ...
5h
Schizophrenia Treatment Revolution: FDA Approves Bristol Myers Squibb's Cobenfy As First New Class Of Treatment In More Than 3 Decades
Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults. Bristol-Myers added the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Promotes watch collection
Pleads not guilty
'Harry Potter' star dies
Stadiums to serve as shelters
World's oldest cheese found
Targeted Black residents?
Killer gets life sentence
50/50 ball ownership suit
Producing doc on Diddy
Ending password-sharing
Boxes to distribute Narcan
Urgent safety alert for 737s
Chinese submarine sank
WI duplicate ballot flap
More executives leave
On Secret Service failures
Heads to US-Mexico border
NC board removes 747K
Fake Biden robocalls fine
NIH finds misconduct
ISR targets Hezbollah HQ
US charges three Iranians
Capital goods orders up
Military recruiting rebounds
Feedback